Investigator-sponsored trials (ISTs) — clinical studies initiated and conducted by individual investigators rather than pharmaceutical sponsors — represent a substantial and growing segment of clinical research activity. The Association of American Medical Colleges (AAMC) estimates that academic medical centers conduct thousands of ISTs annually, ranging from single-site feasibility studies to multi-site investigator networks. What distinguishes ISTs from commercially sponsored trials is not their scientific ambition but their administrative infrastructure — or the frequent lack of it.
In a sponsor-run trial, a dedicated regulatory affairs team manages IND submissions, safety reporting, and IRB coordination. A CRO manages site communication and monitoring. In an IST, all of these functions fall on the investigator, their coordinator, and — if they are fortunate — a part-time grants administrator. The result is a compliance environment where deadlines slip, safety reports arrive late to the investigator network, and IRB lapses occur not through negligence but through sheer administrative overload.
IRB Continuing Review: The Deadline That Doesn't Move
IRB approval for a clinical study must be renewed at intervals not exceeding one year, and the consequences of a lapse in approval are immediate and severe: enrollment must halt, ongoing subjects may require notification, and the lapse must be reported to the IRB, the sponsor (if applicable), and potentially the FDA. Despite this, IRB continuing review lapses are one of the most commonly cited findings in federal compliance reviews of academic research programs.
A VA supporting an IST coordinator maintains a prospective IRB calendar across all active protocols, sets multi-week advance reminders for continuing review submission deadlines, tracks the submission status and IRB review timeline, and flags any delays in IRB response that could jeopardize uninterrupted approval. When continuing review submissions require assembly of enrollment logs, adverse event summaries, and protocol deviation reports, the VA coordinates document collection from the coordinator and PI ahead of the submission deadline.
IND Safety Report Distribution: Protecting the Investigator Network
When an IST holds an IND and involves multiple sub-investigators or a distributed site network, the sponsor-investigator bears responsibility for distributing IND annual reports and expedited safety reports (IND Safety Reports under 21 CFR 312.32) to all participating investigators. This distribution must be documented — investigators must acknowledge receipt, and that acknowledgment must be filed.
A VA manages this distribution workflow: generating distribution lists from the investigator roster, sending safety reports via tracked communication channels, collecting acknowledgment confirmations, maintaining a distribution log with timestamps, and archiving all correspondence in the regulatory file. This function, simple in execution but critical in compliance, is one of the most commonly deferred administrative tasks in IST operations.
Source Document Verification Scheduling
ISTs subject to FDA oversight must maintain source documents — original records from which CRF data can be verified — in good order. Sponsor-monitors or internal auditors periodically conduct source document verification (SDV) visits, which must be scheduled, prepared for, and documented. For ISTs without a CRO, this monitoring function falls on the investigator's own team.
A VA coordinates SDV visit scheduling, prepares site binders and document access for the monitor, tracks monitoring findings and open action items, and ensures corrective action responses are completed within the required timeframe. This function directly supports FDA inspection readiness for ISTs under active IND.
Grant Reporting Coordination: The Academic Research Obligation
ISTs funded through NIH, foundation grants, or institutional funds carry grant reporting obligations that parallel their regulatory obligations. Progress reports, financial reports, and protocol modification notifications must be submitted on defined schedules to the funding agency.
A VA maintains the grant reporting calendar, assembles progress report components from the PI and study team, formats reports to funder specifications, and submits them through the appropriate institutional channels. For ISTs with multiple funding sources, the VA manages the reporting calendar across all funders, ensuring no reporting deadline is missed.
Academic investigators and IST coordinators can find experienced VA support at Stealth Agents.
Sources
- Association of American Medical Colleges (AAMC), Clinical Research Infrastructure Report 2024
- FDA, 21 CFR 312.32 — IND Safety Reporting
- HHS Office for Human Research Protections (OHRP), IRB Compliance Activity Report 2023
- NIH Office of Research Integrity, Grant Reporting Requirements